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hepatitis co-infection liver damage was also 
caused by other reasons: 60% had history of 
drug using, drug toxicity or opportunistic 
infections. 30% of all patients were receiving 
ART, 65% were exposed to TB therapy.
C onclusion : Results of the performed analysis 
show that co-infection of HIV / AIDS with viral 
hepatitis B and C is presented in significant part 
in total mortality structure. This trend is existing 
currently and during recent years. The presence 
of co-infection complicates the course of both 
infections and promotes more rapid progression 
of liver disease. The risk of unfavorable 
outcome is increased by such factors as drug 
use or use of hepatotoxic medicine. It is 
necessary to pay more attention to timely 
diagnosis of HIV / hepatitis B co-infection with 
the purpose of timely treatment of the patients.
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Background: With appearance of antiretroviral 
therapy (ART), the life quality and length of HIV 
infected patients has significantly improved. 
Patients co-infected with HIV / HBV receive 
ART scheme including nucleoside reverse 
transcriptase inhibitors (NRTI), 3TC and TDF, 
with regard to their effect on hepatitis B virus. 
However NRTI are not acting on hepatitis C co­
infection. So, this category of patients requires 
additional antiviral drugs. To plan the financial 
costs of the State Program 'Antihepatitis' and
optimize the management of patients with HIV / 
viral hepatitis co-infection on ART, it is 
necessary to study the spread of these 
conditions and their structure in the cohort.
Materials & m ethods: We analyzed the 
prevalence of serological markers of HBV and 
HCV in a cohort of 501 patients with confirmed 
HIV infection in our clinic.
All patients were conducted clinical and 
laboratory examination, which included 
evaluation (CD4), HIV RNA load, biochemical 
tests, serological markers of opportunistic 
infections and viral hepatitis B (HbsAg, HbeAg, 
Ab HBeAg), C (Ab HCV), Ab to hepatitis D. 
According to WHO classification, 1st disease 
stage was diagnosed in 9 patients (1.8%), 2nd in 
49 (9.8%), 3rd in 164 (32.7%), 4th in 279 (55.7%).
Results: Chronic liver diseases were revealed 
in 167 patients (33.3%): HCV markers in 53 
(10.6%), of hepatitis B in 15 (2.3%), of hepatitis 
B + C in 48 (9.6%), of hepatitis of unknown 
etiology in 44 (8.8%), of liver cirrhosis in 7 
(1.4%). Patients with viral hepatitis B and C 
were divided into 2 groups: receiving ART for at 
least 2 years (1st group, n = 62), without ART 
(2nd group, n = 41). The 1st group patients 
received schemes of ART which included NRTI, 
lamivudine and tenofovir (3TC and TDF) 
Comparative analysis showed that viral markers 
of hepatitis B and C are found in 1st and 2nd 
groups with different frequency. The prevalence 
of chronic hepatitis B markers among 1st group 
is 2.9%, which is almost 9 times lower than in 
the 2nd group (19.1%) (p<0.05). Spread of HCV 
in both groups (36.8% and 41.2% respectively) 
significantly exceeded prevalence of HBV (P 
<0.05). At the same time, the frequency of HCV 
frequency was mainly similar between 1st and 
2nd groups.
C onclusion : It was shown that co-infection of 
HIV / hepatitis occurs in more than 1/3 of 
patients. The structure of HIV / hepatitis co­
infection in the total cohort shows prevalence of 
HCV-infection. Less frequently mixed infection 
(HBV + HCV) and monoinfection are seen. The 
prevalence of chronic hepatitis B was 
significantly lower in patients receiving ART, 
which indicates the effectiveness of ART in two 
directions, to restrict replication of HIV and HBV. 
Obtained results allow more effective 
management of patients with HIV / HCV and/or 
HBV co-infection.
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Background: Viral hepatitis C is a common co­
morbidities in HIV-infected individuals. In terms 
immunodeficiency virus C replication increases, 
leading to rapid progression of liver cirrhosis 
[Sulkowski WS, Mehta SH, Torbenson MS, at 
al., 2007]. The advent of potent ART has 
modified the main causes of morbidity and 
mortality in HIV-infected persons. Non-AIDS 
conditions are now replacing opportunistic 
infections and malignancies as the majority for 
HIV-infected patients [Deeks SG,Phillips AN, 
2009]. It showed that chronic hepatitis C is the 
main factor responsible for the unfavourable 
and fatal outcome in the patients under regular 
medical care [Paula Tuma, Jose Medrano, 
Salvador Resino et al., 2010]. The low number 
of CD4 + T lymphocytes, male gender, older 
age, alcohol abuse are aggravating factors on 
the course of chronic hepatitis C and accelerate 
its progression to liver cirrhosis and 
hepatocellular carcinoma [Clinical protocol for 
diagnosis and treatment of hepatitis C in adults 
with HIV, MH Ukraine, 2008, p. 3]. Objective: To 
investigate the effect of the drug ribonucleic 
acid to improve the functional state of the liver 
in HIV-infected persons with viral C cirrhosis.
Material & Methods: Under the supervision 
were 24 HIV-infected persons aged 36-54 years 
with chronic hepatitis C viral cirrhosis classes A
- 4 patients and B - 20. Functional status of liver 
was determined by the parameters pigment 
metabolism, cholestasis and cytolysis (bilirubin, 
alkaline phosphatase, cholesterol, prothrombin 
index, albumin, ALT, AST). Digital material were 
worked on the program Exeel using t Student's 
criteria for small sample.
Results: In complex pathogenetic therapy the 
patients received a drugs arginine glutamate 
(Glutargin), silymarin (Carsil), detoxification 
infusion therapy, veroshpiron used if the
Abstract: 18 presence of ascites. In addition 12 patients who 
had cirrhosis classes A - 2 persons and B-10 
received drug ribonucleic acid (Nuklex, 
producer Ukraine) 2 capsules three times a day
- 30 days. In patients who received only basic 
therapy (12 patients with cirrhosis: A -  2 person 
and B -  10) functional state of the liver improved 
to 25-38 days of treatment - disappear ascites, 
jaundice decreased symptom, patients feel 
slightly upgraded. Some indexes were retained 
at elevated level: bilirubin- 86,53 ± 11,91 
mmol/L, ALT -109,2 ± 13,4 U/L, alkaline 
phosphatase 438,17 ± 52,82 U/L, but 
prothrombin index (69,90 ± 3.27%) and albumin 
(24,08 ± 3,18 g / l) were decreased. However, 
in patients were treated with ribonucleic acid the 
symptom of jaundice decreased at the 9-15 
days of treatment, the ascites significantly 
reduced in the same term. After the treatment 
the some biochemical parameters were closer 
to normal than in patients with the comparison 
group. The level of bilirubin was 45,27 ± 11,91 
mmol/L, P<0,05; ALT - 69,2±8,26 IU/L, P<0,05; 
alkaline phosphatase - 241,54±18,72, P<0,05; 
prothrombin index 76,90±2,93%; albumin - 
34,08±3,31 g/L, P <0,05.
C onclusion : Use the drug ribonucleic acid as 
a part of pathogenetic therapy of HIV-infected 
patients suffering from viral C cirrhosis 
improves the functional state of the liver.
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